Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA)

Several brokerages have updated their recommendations and price targets on shares of Taysha Gene Therapies (NASDAQ: TSHA) in the last few weeks:

• 11/15/2024 – Taysha Gene Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. from $6.00 to $8.00. They now have a “buy” rating on the stock.
• 11/14/2024 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
• 11/12/2024 – Taysha Gene Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
• 11/12/2024 – Taysha Gene Therapies had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
• 11/12/2024 – Taysha Gene Therapies had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.

Taysha Gene Therapies Trading Up 10.7 %

NASDAQ TSHA opened at $2.28 on Tuesday. The company’s 50-day simple moving average is $1.98 and its two-hundred day simple moving average is $2.38. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.22 and a current ratio of 5.51. The company has a market capitalization of $467.27 million, a price-to-earnings ratio of 3.62 and a beta of 0.44. Taysha Gene Therapies, Inc. has a one year low of $1.19 and a one year high of $4.32.

Hedge Funds Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. StemPoint Capital LP purchased a new stake in Taysha Gene Therapies during the 1st quarter valued at about $3,122,000. Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after buying an additional 14,294,445 shares during the period. Artal Group S.A. lifted its holdings in Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after purchasing an additional 24,444 shares in the last quarter. Quantum Private Wealth LLC increased its stake in shares of Taysha Gene Therapies by 4.6% during the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock worth $1,636,000 after purchasing an additional 32,000 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies in the 2nd quarter worth about $1,018,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.